Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.

Despite major advances in the treatment of non-Hodgkin lymphoma (NHL), including the use of chemotherapeutic agents and the anti-CD20 antibody rituximab, the majority of patients eventually relapse, and salvage treatments with non-cross-resistant compounds are needed to further improve patient survival. Here, we evaluated the antitumor effects of the microtubule destabilizing agent monomethyl auristatin E (MMAE) conjugated to the humanized anti-CD19 antibody hBU12 via a protease-sensitive valine-citrulline (vc) dipeptide linker. hBU12-vcMMAE induced potent tumor cell killing against rituximab-sensitive and -resistant NHL cell lines. CD19 can form heterodimers with CD21, and high levels of CD21 were reported to interfere negatively with the activity of CD19-targeted therapeutics. However, we observed comparable internalization, intracellular trafficking, and drug release in CD21(low) and CD21(high), rituximab-sensitive and -refractory lymphomas treated with hBU12-vcMMAE. Furthermore, high rates of durable regressions in mice implanted with these tumors were observed, suggesting that both rituximab resistance and CD21 expression levels do not impact on the activity of hBU12-vcMMAE. Combined, our data suggest that hBU12-vcMMAE may represent a promising addition to the treatment options for rituximab refractory NHL and other hematologic malignancies, including acute lymphoblastic leukemia.

[1]  I. Pastan,et al.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. , 2008, Cancer research.

[2]  J. Leonard,et al.  Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma , 2008 .

[3]  M. Czuczman,et al.  Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression , 2008, Clinical Cancer Research.

[4]  M. Czuczman,et al.  Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels , 2008, Clinical Cancer Research.

[5]  H. Koeppen,et al.  High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate , 2007, British journal of haematology.

[6]  Baoqing Guo,et al.  Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. , 2007, Anti-cancer drugs.

[7]  V. Adamo,et al.  The role of Aurora-A inhibitors in cancer therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  B. Bonavida,et al.  Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. , 2007, Cancer research.

[9]  A. Ebens,et al.  Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. , 2006, Blood.

[10]  P. Carter.  Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.

[11]  Damon L. Meyer,et al.  Lysosomal Trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates* , 2006, Journal of Biological Chemistry.

[12]  Rania M. Seliem,et al.  Immunophenotypic Changes and Clinical Outcome in B-Cell Lymphomas Treated with Rituximab , 2006, Applied immunohistochemistry & molecular morphology : AIMM.

[13]  Damon L. Meyer,et al.  Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. , 2006, Bioconjugate chemistry.

[14]  T. Tedder,et al.  Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Maloney.  Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Michael M C Sun,et al.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. , 2005, Bioconjugate chemistry.

[17]  Damon L. Meyer,et al.  Efficient Elimination of B-Lineage Lymphomas by Anti-CD20–Auristatin Conjugates , 2004, Clinical Cancer Research.

[18]  P. Carter,et al.  Identification and validation of cell surface antigens for antibody targeting in oncology. , 2004, Endocrine-related cancer.

[19]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[20]  L. Goodglick,et al.  Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab , 2004, Cancer Research.

[21]  J. Jaffrezou,et al.  Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. , 2004, Blood.

[22]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[23]  A. Órfão,et al.  Immunophenotypic analysis of Waldenstrom's macroglobulinemia. , 2003, Seminars in oncology.

[24]  Peter D. Senter,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .

[25]  V. Facchinetti,et al.  Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. , 2003, Haematologica.

[26]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[27]  A. Wahl,et al.  Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. , 2002, The Journal of organic chemistry.

[28]  P. Chu,et al.  Recurrent B-cell Neoplasms After Rituximab Therapy: An Immunophenotypic and Genotypic Study , 2002, Leukemia & lymphoma.

[29]  B. Bonavida,et al.  Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. , 2001, Cancer research.

[30]  M. Czuczman,et al.  Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  D. Fearon,et al.  Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. , 2000, Annual review of immunology.

[32]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. James,et al.  FDA approves new kind of lymphoma treatment. Food and Drug Administration. , 1997, AIDS treatment news.

[34]  K. Campbell,et al.  Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81 , 1997, The EMBO journal.

[35]  E. Vitetta,et al.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Levy,et al.  Normal Lymphocyte Development but Delayed Humoral Immune Response in CD81-null Mice , 1997, The Journal of experimental medicine.

[37]  B. Teicher,et al.  Anticancer Drug Development Guide , 1997, Cancer Drug Discovery and Development.

[38]  N. Ling,et al.  Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours. , 1995, British Journal of Cancer.

[39]  B. Koller,et al.  Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. , 1995, Immunity.

[40]  Liangji Zhou,et al.  The CD19/CD21 signal transduction complex of B lymphocytes. , 1994, Immunology today.

[41]  I. Bernstein,et al.  Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. , 1994, Blood.

[42]  L. Picker,et al.  Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest. , 1994, Blood.

[43]  D. Fearon,et al.  Functional dissection of the CD21/CD19/TAPA-1/Leu-13 complex of B lymphocytes , 1993, The Journal of experimental medicine.

[44]  T. Tedder,et al.  The CD19 signal transduction complex of B lymphocytes. Deletion of the CD19 cytoplasmic domain alters signal transduction but not complex formation with TAPA-1 and Leu 13. , 1993, Journal of immunology.

[45]  A. Boesen,et al.  Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. , 1993, Blood.

[46]  A. Farr,et al.  Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. , 1989, Cancer research.

[47]  M. Wick,et al.  Detailed Studies on Expression and Function of CD19 Surface Determinant by Using B43 Monoclonal Antibody and the Clinical Potential of Anti-CD19 Immunotoxins , 1988 .

[48]  A. Fauci,et al.  Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. , 1988, Blood.

[49]  M. Cooper,et al.  Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. , 1984, Journal of immunology.

[50]  G. Marti,et al.  B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. , 1983, Journal of immunology.